Rikos schreef op 4 september 2025 17:36:
[...]
De misleiding ten top van deze poster.
Bron: website Kalvista
ir.kalvista.com/news-releases/news-re...Jul 07, 2025
First new on-demand HAE treatment in over a decade, with potential to transform management of the disease
Data demonstrated rapid symptom relief and attack resolution regardless of attack severity, location, age, or use of long-term prophylaxis, and well-established safety profile
Management to host conference call today at 8:30 a.m. ET
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Jul. 7, 2025-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved EKTERLY® (sebetralstat), a novel plasma kallikrein inhibitor,
for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. EKTERLY is the first and only oral on-demand treatment for HAE.
Aextracker is er al meerdere keren op gewezen dat zijn beweringen omtrent Ekterly compleet zelf verzonnen zijn en nu begint aextracker ook nog te liegen over het feit dat Kalvista aangeeft dat Ekterly voor profylaxe bedoelt is!!!!!
Helaas weer de zoveelste misleiding van poster aextracker.
M.i. dan